These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 39108262)

  • 1. Dynamics of peripheral blood inflammatory index predict tumor pathological response and survival among patients with locally advanced non-small cell lung cancer who underwent neoadjuvant immunochemotherapy: a multi-cohort retrospective study.
    Zhai W; Zhang C; Duan F; Xie J; Dai S; Lin Y; Yan Q; Rao B; Li L; Zhou Y; Zhao Z; Long H; Wang J
    Front Immunol; 2024; 15():1422717. PubMed ID: 39108262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combined model using pre-treatment CT radiomics and clinicopathological features of non-small cell lung cancer to predict major pathological responses after neoadjuvant chemoimmunotherapy.
    Wang F; Yang H; Chen W; Ruan L; Jiang T; Cheng L; Jiang H; Fang M
    Curr Probl Cancer; 2024 Jun; 50():101098. PubMed ID: 38704949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study.
    Li C; Wu J; Jiang L; Zhang L; Huang J; Tian Y; Zhao Y; Liu X; Xia L; E H; Gao P; Hou L; Yang M; Ma M; Su C; Zhang H; Chen H; She Y; Xie D; Luo Q; Chen C
    Cancer Immunol Immunother; 2023 Mar; 72(3):783-794. PubMed ID: 36056951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tertiary lymphoid structures combined with biomarkers of inflammation are associated with the efficacy of neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: A retrospective study.
    Xu F; Zhu H; Xiong D; Wang K; Dong Y; Li L; Yuan S
    Thorac Cancer; 2024 Jan; 15(2):172-181. PubMed ID: 38057283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns and clinical outcomes of patients with resectable non-small cell lung cancer receiving neoadjuvant immunochemotherapy: A large-scale, multicenter, real-world study (NeoR-World).
    Yang Z; Wang S; Yang H; Jiang Y; Zhu L; Zheng B; Fu H; Ma J; Xie H; Wang Z; He H; Xia C; Li R; Xu J; Han J; Huang X; Li Y; Zhao B; Ni C; Xing H; Chen Y; Wang J; Jiang Y; Song Y; Mao Y; Chen C; Yao F; Zhang G; Hu J; Xue Q; Gao S; He J;
    J Thorac Cardiovasc Surg; 2024 Oct; 168(4):1245-1258.e17. PubMed ID: 38342430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non-small cell lung cancer patients with neoadjuvant immunotherapy.
    Huai Q; Luo C; Song P; Bie F; Bai G; Li Y; Liu Y; Chen X; Zhou B; Sun X; Guo W; Gao S
    Cancer Sci; 2023 Dec; 114(12):4484-4498. PubMed ID: 37731264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes associated with neoadjuvant therapy for the treatment of resectable non-small cell lung cancer in real-world practice.
    Huang X; Pang G; Mao Z; Li B; Teng Z; Yang Y; Qiu Z; Chen X; Wang P
    Clin Respir J; 2024 May; 18(5):e13761. PubMed ID: 38693705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The predictive value of
    Yin X; Li J; Chen B; Liu K; Hu S
    Lung Cancer; 2023 Dec; 186():107389. PubMed ID: 37820538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Easily applicable predictive score for MPR based on parameters before neoadjuvant chemoimmunotherapy in operable NSCLC: a single-center, ambispective, observational study.
    Hu M; Li X; Lin H; Lu B; Wang Q; Tong L; Li H; Che N; Hung S; Han Y; Shi K; Li C; Zhang H; Liu Z; Zhang T
    Int J Surg; 2024 Apr; 110(4):2275-2287. PubMed ID: 38265431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy.
    Weissferdt A; Pataer A; Vaporciyan AA; Correa AM; Sepesi B; Moran CA; Wistuba II; Roth JA; Shewale JB; Heymach JV; Kalhor N; Cascone T; Hofstetter WL; Lee JJ; Swisher SG
    Clin Lung Cancer; 2020 Jul; 21(4):341-348. PubMed ID: 32279936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [
    Yang M; Li X; Cai C; Liu C; Ma M; Qu W; Zhong S; Zheng E; Zhu H; Jin F; Shi H
    Eur Radiol; 2024 Jul; 34(7):4352-4363. PubMed ID: 38127071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CT-based quantification of intratumoral heterogeneity for predicting pathologic complete response to neoadjuvant immunochemotherapy in non-small cell lung cancer.
    Ye G; Wu G; Zhang C; Wang M; Liu H; Song E; Zhuang Y; Li K; Qi Y; Liao Y
    Front Immunol; 2024; 15():1414954. PubMed ID: 38933281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological response and tumor stroma immunogenic features predict long-term survival in non-small cell lung cancer after neoadjuvant chemotherapy.
    Wang S; Sun X; Dong J; Liu L; Zhao H; Li R; Yang Z; Cheng N; Wang Y; Fu L; Yi H; Lv Z; Huo H; Jin D; Mao Y; Yang L
    Cell Oncol (Dordr); 2024 Jun; 47(3):1005-1024. PubMed ID: 38319500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring clinical factors to predict the survival of patients with resectable non-small cell lung cancer with neoadjuvant immunotherapy.
    Zhang M; Yan M; Xiao Z; Li Y; Liu Z; Zhang P; Wang X; Zhang L; Zhang Z
    Eur J Cardiothorac Surg; 2024 Oct; 66(4):. PubMed ID: 39271146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep learning for predicting major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: A multicentre study.
    She Y; He B; Wang F; Zhong Y; Wang T; Liu Z; Yang M; Yu B; Deng J; Sun X; Wu C; Hou L; Zhu Y; Yang Y; Hu H; Dong D; Chen C; Tian J
    EBioMedicine; 2022 Dec; 86():104364. PubMed ID: 36395737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of K
    Wang D; Liu S; Fu J; Zhang P; Zheng S; Qiu B; Liu H; Ye Y; Guo J; Zhou Y; Jiang H; Yin S; He H; Xie C; Liu H
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38910009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole slide image-based weakly supervised deep learning for predicting major pathological response in non-small cell lung cancer following neoadjuvant chemoimmunotherapy: a multicenter, retrospective, cohort study.
    Han D; Li H; Zheng X; Fu S; Wei R; Zhao Q; Liu C; Wang Z; Huang W; Hao S
    Front Immunol; 2024; 15():1453232. PubMed ID: 39372403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delta-radiomics features for predicting the major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer.
    Han X; Wang M; Zheng Y; Wang N; Wu Y; Ding C; Jia X; Yang R; Geng M; Chen Z; Zhang S; Zhang K; Li Y; Liu J; Gu J; Liao Y; Fan J; Shi H
    Eur Radiol; 2024 Apr; 34(4):2716-2726. PubMed ID: 37736804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic alteration in SULmax predicts early pathological tumor response and short-term prognosis in non-small cell lung cancer treated with neoadjuvant immunochemotherapy.
    Sun T; Huang S; Jiang Y; Yuan H; Wu J; Liu C; Zhang X; Tang Y; Ben X; Tang J; Zhou H; Zhang D; Xie L; Chen G; Zhao Y; Wang S; Xu H; Qiao G
    Front Bioeng Biotechnol; 2022; 10():1010672. PubMed ID: 36277407
    [No Abstract]   [Full Text] [Related]  

  • 20. [Comparison of Short-term Efficacy of Neoadjuvant Immunotherapy Combined with Chemotherapy and Surgery Alone for Locally Advanced Resectable 
Non-small Cell Lung Cancer].
    Li H; Liu Q; Li B; Chen Y; Lin J; Meng Y; Feng H; Zheng Z; Hui Y
    Zhongguo Fei Ai Za Zhi; 2024 Jun; 27(6):421-430. PubMed ID: 39026493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.